About KCI A Spirit of Innovation At KCI, we are devoted to advancing the science of healing and positively impacting patient care by developing customer-driven innovation to meet the evolving needs of healthcare professionals. For over 35 years, we have led the way in the development of new technologies, medicines and therapies designed to make wound healing more manageable for caregivers and more comfortable for patients around the world.
Caresyntax® is a technology and services platform that helps hospitals reduce surgical risk and improveoutcomes
DECISIOInsight® provides a real-time view of the patient’s story and status changes at a glance using real-time clinical surveillance with data visualization. DECISIOInsight® proactively identifies risk which helps clinicians make faster, more accurate and often life-saving treatment decision.
Designs for Vision
Designs for Vision is the trusted brand that surgeons rely on for quality, reliability and durability. Our Surgical Telescopes provide the TRUE magnification expeted for demanding procedures.
HCA Training Program Outreach
HCA’s Training Program Outreach (TPO) assists residents and fellows with the transition from training to practice – including financial assistance to help pay for it. We strive to educate residents and fellows about the process of transitioning and ensure you are prepared to accept the practicing position that fits your criteria.
IER Innovations is dedicated in providing high-insentisy ultrasound devices for pain, trauma, mood disorders, alopecia, circulation and nocturnal sleep disorders. We provide LE, USE, LLLT and high-insensity FDA approved theraphies and treatments worldwide. Our products penetrate deep below the surface of the skin, promote cellular repair and collagen production, improve elasticty, increase blood circulation and encourage lymphastic drainage.
Shire is now part of Takeda.
Takeda is a global, values-based, R&D-driven biopharmaceutical leader headquartered in Japan, committed to bringing Better Health and a Brighter Future to patients by translating science into highly-innovative medicines. Takeda focuses its R&D efforts on four therapeutic areas: Oncology, Gastroenterology (GI), Neuroscience and Rare Diseases. We also make targeted R&D investments in Plasma-Derived Therapies and Vaccines. We are focusing on developing highly innovative medicines that contribute to making a difference in people’s lives by advancing the frontier of new treatment options and leveraging our enhanced collaborative R&D engine and capabilities to create a robust, modality-diverse pipeline.”